View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAequus Pharmaceuticals 将来の成長Future 基準チェック /06現在、 Aequus Pharmaceuticalsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長23.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Sep 23Aequus Pharmaceuticals Inc. Appoints Giovanni Di Genova to the Board of Directors, Effective from September 12, 2025Aequus Pharmaceuticals Inc. announced Giovanni Di Genova has agreed to join the Aequus Board of Directors, subject to the completion of his PIF and TSX approval, effective September 12th, 2025. Aequus is pleased to welcome Giovanni Di Genova as a new director and are eager to work with him on the future ahead. Giovanni Di Genova earned his Bachelor of Science and Bachelor of Pharmacy from McGill University and Universit de Montral, respectively. He began his career in the specialty compounding pharmacy &pharmaceutical industry nearly 35 years ago, covering multiple therapeutic areas including ophthalmology, oncology, gastrointestinal, neurological, infectious, and autoimmune diseases. John has held positions in both innovative and generic pharmaceutical organizations, with roles in API/Materials Management, Production, Sales, Marketing and Business Development. He has a proven track record in strategy and operations, including strong business development experience with M&A, licensing, co-development, and supply agreements. John started his career at Ayerst and PharmaScience, and most recently, served as CEO and founder of Advanced Dosage Forms, a private firm involved in the licensing, sales, marketing, and distribution of high-barrier-to-market niche pharmaceuticals.お知らせ • Sep 19Aequus Pharmaceuticals Inc., Annual General Meeting, Oct 29, 2025Aequus Pharmaceuticals Inc., Annual General Meeting, Oct 29, 2025. Location: british columbia, vancouver CanadaReported Earnings • Nov 10Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 3Q 2023)Third quarter 2024 results: CA$0.005 loss per share (improved from CA$0.006 loss in 3Q 2023). Revenue: CA$148.3k (up CA$135.0k from 3Q 2023). Net loss: CA$614.7k (loss narrowed 24% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 53% per year, which means it is performing significantly worse than earnings.Reported Earnings • Sep 01Second quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 2Q 2023)Second quarter 2024 results: CA$0.005 loss per share (in line with 2Q 2023). Revenue: CA$161.4k (up 64% from 2Q 2023). Net loss: CA$683.0k (loss narrowed 2.5% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings.Reported Earnings • May 02Full year 2023 earnings released: CA$0.022 loss per share (vs CA$0.024 loss in FY 2022)Full year 2023 results: CA$0.022 loss per share (improved from CA$0.024 loss in FY 2022). Revenue: CA$254.9k (down 82% from FY 2022). Net loss: CA$2.96m (loss narrowed 7.6% from FY 2022).New Risk • Dec 01New major risk - Revenue and earnings growthEarnings have declined by 0.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.8m free cash flow). Share price has been highly volatile over the past 3 months (75% average weekly change). Negative equity (-CA$3.6m). Earnings have declined by 0.7% per year over the past 5 years. Revenue is less than US$1m (CA$587k revenue, or US$433k). Market cap is less than US$10m (€2.69m market cap, or US$2.93m).Reported Earnings • Sep 03Second quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 2Q 2022)Second quarter 2023 results: CA$0.005 loss per share (improved from CA$0.006 loss in 2Q 2022). Revenue: CA$98.4k (down 72% from 2Q 2022). Net loss: CA$700.9k (loss narrowed 9.2% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.お知らせ • Aug 25Aequus Pharmaceuticals Inc. Announces Launch of Zimed PF in CanadaAequus Pharmaceuticals Inc. announced the launch of Zimed® PF, the first preservative-free multi-dose Bimatoprost for glaucoma patients in Canada.お知らせ • Aug 19Aequus Pharmaceuticals Inc. Announces Pause in Sales of Evolve Intensive Eyedrop and Intensive Gel Products in CanadaAequus Pharmaceuticals Inc. announced the pause of sales of its Evolve Intensive eyedrop and Intensive gel products in Canada. The manufacturer, Medicom Healthcare (UK), is in the process of changing its MDSAP provider. The switch was necessitated by the existing Notified Body being unable to offer all relevant global certifications. Until this process is completed, Aequus Pharmaceuticals will pause sales of the class leading Evolve® range of products in the Canadian market. The company look forward to Evolve® returning to patients in Canada as soon as MDSAP Certification is issued. Aequus and Medicom Healthcare assure valued customers and eyecare professionals that the Evolve® Intensive eyedrops and gel will return to the Canadian market soon. The Company remains steadfast in its commitment to delivering innovative solutions that enhance the well-being of patients across Canada.Reported Earnings • Jun 02First quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.007 loss in 1Q 2022)First quarter 2023 results: CA$0.006 loss per share (improved from CA$0.007 loss in 1Q 2022). Revenue: CA$92.3k (down 70% from 1Q 2022). Net loss: CA$744.3k (loss narrowed 19% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.お知らせ • May 27Aequus Pharmaceuticals Inc., Annual General Meeting, Jul 25, 2023Aequus Pharmaceuticals Inc., Annual General Meeting, Jul 25, 2023.Reported Earnings • Dec 01Third quarter 2022 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 3Q 2021)Third quarter 2022 results: CA$0.004 loss per share (further deteriorated from CA$0.003 loss in 3Q 2021). Revenue: CA$347.9k (down 51% from 3Q 2021). Net loss: CA$500.5k (loss widened 31% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Marc Lustig was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 31Second quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.004 loss in 2Q 2021)Second quarter 2022 results: CA$0.006 loss per share (down from CA$0.004 loss in 2Q 2021). Revenue: CA$346.5k (down 47% from 2Q 2021). Net loss: CA$772.1k (loss widened 61% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Board Change • Jul 21Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Marc Lustig was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Dec 31High number of new directorsIndependent Director Marc Lustig was the last director to join the board, commencing their role in 2021.Reported Earnings • Nov 04Third quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: CA$712.0k (up 15% from 3Q 2020). Net loss: CA$381.5k (loss widened 52% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Director Overboarding • Sep 02Director Marc Lustig has joined 5th company boardMarc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Director Overboarding • Sep 02Director Marc Lustig has joined 5th company boardMarc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Director Overboarding • Sep 02Director Marc Lustig has joined 5th company boardMarc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Director Overboarding • Sep 02Director Marc Lustig has joined 5th company boardMarc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Reported Earnings • Aug 31Second quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 2Q 2020)The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: CA$651.5k (up 20% from 2Q 2020). Net loss: CA$479.0k (loss widened 116% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Reported Earnings • Jun 01First quarter 2021 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: CA$491.8k (down 15% from 1Q 2020). Net loss: CA$621.7k (loss widened 53% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 25Full year 2020 earnings released: CA$0.011 loss per share (vs CA$0.039 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: CA$2.59m (up 59% from FY 2019). Net loss: CA$1.05m (loss narrowed 66% from FY 2019). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Reported Earnings • Dec 01Third quarter 2020 earnings released: CA$0.003 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: CA$619.0k (up 67% from 3Q 2019). Net loss: CA$251.9k (loss narrowed 62% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Aequus Pharmaceuticals は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:AEQ - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20251-2-1-1N/A12/31/20241-2-2-2N/A9/30/20240-3-2-2N/A6/30/20240-3-3-3N/A3/31/20240-3-3-3N/A12/31/20230-3-2-2N/A9/30/20231-3-2-2N/A6/30/20231-3-2-2N/A3/31/20231-3-2-2N/A12/31/20221-3-2-2N/A9/30/20222-3-2-2N/A6/30/20222-2-2-2N/A3/31/20223-2-1-1N/A12/31/20213-2-1-1N/A9/30/20213-2-1-1N/A6/30/20213-2-1-1N/A3/31/20213-1-1-1N/A12/31/20203-1-1-1N/A9/30/20202-2-1-1N/A6/30/20202-2-1-1N/A3/31/20202-3-2-2N/A12/31/20192-3-2-2N/A9/30/20191-3-2-2N/A6/30/20191-3-2-2N/A3/31/20191-3-2-2N/A12/31/20181-3N/A-3N/A9/30/20182-3N/A-3N/A6/30/20181-3N/A-3N/A3/31/20181-4N/A-3N/A12/31/20171-4N/A-4N/A9/30/20171-4N/A-4N/A6/30/20171-5N/A-4N/A3/31/20171-5N/A-4N/A12/31/20161-5N/A-4N/A9/30/20161-5N/A-5N/A6/30/20160-5N/A-4N/A3/31/20160-5N/A-4N/A12/31/2015N/A-5N/A-4N/A9/30/2015N/A-5N/A-4N/A6/30/2015N/A-4N/A-3N/A3/31/2015N/A-3N/A-2N/A12/31/2014N/A-2N/A-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: AEQの予測収益成長が 貯蓄率 ( 1.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: AEQの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: AEQの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: AEQの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: AEQの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: AEQの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/07/23 18:34終値2025/04/25 00:00収益2025/03/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aequus Pharmaceuticals Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Nathan CaliNOBLE Capital Markets, Inc.
お知らせ • Sep 23Aequus Pharmaceuticals Inc. Appoints Giovanni Di Genova to the Board of Directors, Effective from September 12, 2025Aequus Pharmaceuticals Inc. announced Giovanni Di Genova has agreed to join the Aequus Board of Directors, subject to the completion of his PIF and TSX approval, effective September 12th, 2025. Aequus is pleased to welcome Giovanni Di Genova as a new director and are eager to work with him on the future ahead. Giovanni Di Genova earned his Bachelor of Science and Bachelor of Pharmacy from McGill University and Universit de Montral, respectively. He began his career in the specialty compounding pharmacy &pharmaceutical industry nearly 35 years ago, covering multiple therapeutic areas including ophthalmology, oncology, gastrointestinal, neurological, infectious, and autoimmune diseases. John has held positions in both innovative and generic pharmaceutical organizations, with roles in API/Materials Management, Production, Sales, Marketing and Business Development. He has a proven track record in strategy and operations, including strong business development experience with M&A, licensing, co-development, and supply agreements. John started his career at Ayerst and PharmaScience, and most recently, served as CEO and founder of Advanced Dosage Forms, a private firm involved in the licensing, sales, marketing, and distribution of high-barrier-to-market niche pharmaceuticals.
お知らせ • Sep 19Aequus Pharmaceuticals Inc., Annual General Meeting, Oct 29, 2025Aequus Pharmaceuticals Inc., Annual General Meeting, Oct 29, 2025. Location: british columbia, vancouver Canada
Reported Earnings • Nov 10Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 3Q 2023)Third quarter 2024 results: CA$0.005 loss per share (improved from CA$0.006 loss in 3Q 2023). Revenue: CA$148.3k (up CA$135.0k from 3Q 2023). Net loss: CA$614.7k (loss narrowed 24% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 53% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Sep 01Second quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 2Q 2023)Second quarter 2024 results: CA$0.005 loss per share (in line with 2Q 2023). Revenue: CA$161.4k (up 64% from 2Q 2023). Net loss: CA$683.0k (loss narrowed 2.5% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings.
Reported Earnings • May 02Full year 2023 earnings released: CA$0.022 loss per share (vs CA$0.024 loss in FY 2022)Full year 2023 results: CA$0.022 loss per share (improved from CA$0.024 loss in FY 2022). Revenue: CA$254.9k (down 82% from FY 2022). Net loss: CA$2.96m (loss narrowed 7.6% from FY 2022).
New Risk • Dec 01New major risk - Revenue and earnings growthEarnings have declined by 0.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.8m free cash flow). Share price has been highly volatile over the past 3 months (75% average weekly change). Negative equity (-CA$3.6m). Earnings have declined by 0.7% per year over the past 5 years. Revenue is less than US$1m (CA$587k revenue, or US$433k). Market cap is less than US$10m (€2.69m market cap, or US$2.93m).
Reported Earnings • Sep 03Second quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 2Q 2022)Second quarter 2023 results: CA$0.005 loss per share (improved from CA$0.006 loss in 2Q 2022). Revenue: CA$98.4k (down 72% from 2Q 2022). Net loss: CA$700.9k (loss narrowed 9.2% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.
お知らせ • Aug 25Aequus Pharmaceuticals Inc. Announces Launch of Zimed PF in CanadaAequus Pharmaceuticals Inc. announced the launch of Zimed® PF, the first preservative-free multi-dose Bimatoprost for glaucoma patients in Canada.
お知らせ • Aug 19Aequus Pharmaceuticals Inc. Announces Pause in Sales of Evolve Intensive Eyedrop and Intensive Gel Products in CanadaAequus Pharmaceuticals Inc. announced the pause of sales of its Evolve Intensive eyedrop and Intensive gel products in Canada. The manufacturer, Medicom Healthcare (UK), is in the process of changing its MDSAP provider. The switch was necessitated by the existing Notified Body being unable to offer all relevant global certifications. Until this process is completed, Aequus Pharmaceuticals will pause sales of the class leading Evolve® range of products in the Canadian market. The company look forward to Evolve® returning to patients in Canada as soon as MDSAP Certification is issued. Aequus and Medicom Healthcare assure valued customers and eyecare professionals that the Evolve® Intensive eyedrops and gel will return to the Canadian market soon. The Company remains steadfast in its commitment to delivering innovative solutions that enhance the well-being of patients across Canada.
Reported Earnings • Jun 02First quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.007 loss in 1Q 2022)First quarter 2023 results: CA$0.006 loss per share (improved from CA$0.007 loss in 1Q 2022). Revenue: CA$92.3k (down 70% from 1Q 2022). Net loss: CA$744.3k (loss narrowed 19% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
お知らせ • May 27Aequus Pharmaceuticals Inc., Annual General Meeting, Jul 25, 2023Aequus Pharmaceuticals Inc., Annual General Meeting, Jul 25, 2023.
Reported Earnings • Dec 01Third quarter 2022 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 3Q 2021)Third quarter 2022 results: CA$0.004 loss per share (further deteriorated from CA$0.003 loss in 3Q 2021). Revenue: CA$347.9k (down 51% from 3Q 2021). Net loss: CA$500.5k (loss widened 31% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Marc Lustig was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 31Second quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.004 loss in 2Q 2021)Second quarter 2022 results: CA$0.006 loss per share (down from CA$0.004 loss in 2Q 2021). Revenue: CA$346.5k (down 47% from 2Q 2021). Net loss: CA$772.1k (loss widened 61% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Board Change • Jul 21Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Marc Lustig was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Dec 31High number of new directorsIndependent Director Marc Lustig was the last director to join the board, commencing their role in 2021.
Reported Earnings • Nov 04Third quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 3Q 2020)The company reported a soft third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: CA$712.0k (up 15% from 3Q 2020). Net loss: CA$381.5k (loss widened 52% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Director Overboarding • Sep 02Director Marc Lustig has joined 5th company boardMarc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Director Overboarding • Sep 02Director Marc Lustig has joined 5th company boardMarc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Director Overboarding • Sep 02Director Marc Lustig has joined 5th company boardMarc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Director Overboarding • Sep 02Director Marc Lustig has joined 5th company boardMarc Lustig has been appointed to the board of BriaCell Therapeutics Corp. (TSXV:BCT). Lustig now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Reported Earnings • Aug 31Second quarter 2021 earnings released: CA$0.004 loss per share (vs CA$0.003 loss in 2Q 2020)The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: CA$651.5k (up 20% from 2Q 2020). Net loss: CA$479.0k (loss widened 116% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Reported Earnings • Jun 01First quarter 2021 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 1Q 2020)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: CA$491.8k (down 15% from 1Q 2020). Net loss: CA$621.7k (loss widened 53% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 25Full year 2020 earnings released: CA$0.011 loss per share (vs CA$0.039 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: CA$2.59m (up 59% from FY 2019). Net loss: CA$1.05m (loss narrowed 66% from FY 2019). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Reported Earnings • Dec 01Third quarter 2020 earnings released: CA$0.003 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: CA$619.0k (up 67% from 3Q 2019). Net loss: CA$251.9k (loss narrowed 62% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.